These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 22368272)

  • 41. Loss-of-function but not dominant-negative intragenic
    Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
    Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of cytokine receptor-like factor 2 alterations in acute lymphoblastic leukemia: a meta-analysis.
    Jia M; Wang ZJ; Zhao HZ; Shen HP; Cheng YP; Luo ZB; Tang YM
    World J Pediatr; 2015 May; 11(2):126-33. PubMed ID: 25920591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
    Palmi C; Vendramini E; Silvestri D; Longinotti G; Frison D; Cario G; Shochat C; Stanulla M; Rossi V; Di Meglio AM; Villa T; Giarin E; Fazio G; Leszl A; Schrappe M; Basso G; Biondi A; Izraeli S; Conter V; Valsecchi MG; Cazzaniga G; Te Kronnie G
    Leukemia; 2012 Oct; 26(10):2245-53. PubMed ID: 22484421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
    Tasian SK; Loh ML
    Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic significance of
    Wang J; Sun K; Chen WM; Wang X; Li LD; Hao Y; Xu N; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Jiang Q; Qin YZ
    Leuk Lymphoma; 2023 Mar; 64(3):698-706. PubMed ID: 36642937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.
    Imamura T; Kiyokawa N; Kato M; Imai C; Okamoto Y; Yano M; Ohki K; Yamashita Y; Kodama Y; Saito A; Mori M; Ishimaru S; Deguchi T; Hashii Y; Shimomura Y; Hori T; Kato K; Goto H; Ogawa C; Koh K; Taki T; Manabe A; Sato A; Kikuta A; Adachi S; Horibe K; Ohara A; Watanabe A; Kawano Y; Ishii E; Shimada H
    Blood Cancer J; 2016 May; 6(5):e419. PubMed ID: 27176795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
    Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
    Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.
    Maciel ALT; Wolch K; Emerenciano M; Mansur MB
    Genes Chromosomes Cancer; 2022 Jul; 61(7):437-442. PubMed ID: 35253299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia.
    Juárez-Velázquez MDR; Moreno-Lorenzana DL; Martínez Anaya DA; Hernández Monterde EA; Aguilar-Hernández MM; Reyes-León A; Chávez-González MA; López Santiago N; Zapata Tarrés M; Juárez Villegas L; Rivera Sánchez N; Soto Lerma O; Vega-Vega L; Rivera Luna R; Pérez-Vera P
    Cytokine; 2022 Jul; 155():155896. PubMed ID: 35537330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.
    Morak M; Attarbaschi A; Fischer S; Nassimbeni C; Grausenburger R; Bastelberger S; Krentz S; Cario G; Kasper D; Schmitt K; Russell LJ; Pötschger U; Stanulla M; Eckert C; Mann G; Haas OA; Panzer-Grümayer R
    Blood; 2012 Dec; 120(26):5134-42. PubMed ID: 23091296
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.
    Yang YL; Hung CC; Chen JS; Lin KH; Jou ST; Hsiao CC; Sheen JM; Cheng CN; Wu KH; Lin SR; Yu SL; Chen HY; Lu MY; Wang SC; Chang HH; Lin SW; Su YN; Lin DT
    Cancer Sci; 2011 Oct; 102(10):1874-81. PubMed ID: 21740479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
    Attarbaschi A; Morak M; Cario G; Cazzaniga G; Ensor HM; te Kronnie T; Bradtke J; Mann G; Vendramini E; Palmi C; Schwab C; Russell LJ; Schrappe M; Conter V; Mitchell CD; Strehl S; Zimmermann M; Pötschger U; Harrison CJ; Stanulla M; Panzer-Grümayer R; Haas OA; Moorman AV;
    Br J Haematol; 2012 Sep; 158(6):772-7. PubMed ID: 22816614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
    Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
    Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
    Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
    Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
    Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
    Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
    Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
    Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
    Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.